Telomir Pharmaceuticals Files 8-K Report
Ticker: TELO · Form: 8-K · Filed: Jun 18, 2025 · CIK: 1971532
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
Telomir Pharma dropped an 8-K, but didn't say much. What's up?
AI Summary
On June 18, 2025, Telomir Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding the nature of these events, any associated financial figures, or other named parties were provided in the excerpt.
Why It Matters
This filing signals a material event has occurred for Telomir Pharmaceuticals, requiring disclosure to investors. The lack of detail in the provided excerpt leaves investors seeking further information.
Risk Assessment
Risk Level: medium — The filing of an 8-K often indicates significant events, but the lack of specific details in this excerpt creates uncertainty and potential risk for investors.
Key Players & Entities
- Telomir Pharmaceuticals, Inc. (company) — Registrant
- June 18, 2025 (date) — Date of earliest event reported
FAQ
What specific "Other Events" are being reported by Telomir Pharmaceuticals, Inc. on June 18, 2025?
The provided excerpt of the 8-K filing does not specify the nature of the "Other Events."
Does the filing mention any financial impact or transactions related to these "Other Events"?
No, the excerpt does not contain any information about financial impacts or transactions.
Are there any named individuals or other companies involved in the reported "Other Events"?
The provided text does not name any individuals or other companies in relation to the reported events.
What is the principal executive office address for Telomir Pharmaceuticals, Inc. as stated in the filing?
The address is 100 SE 2nd St, Suite 2000, #1009, Miami, Florida.
What is the telephone number listed for Telomir Pharmaceuticals, Inc.?
The telephone number is (786) 396-6723.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 18, 2025 regarding Telomir Pharmaceuticals, Inc. (TELO).